Evaluation of clinical outcomes of vaccinated and unvaccinated patients with hospitalization for COVID-19

被引:2
|
作者
Ozdemir, Yusuf Emre [1 ]
Kizilcay, Burak [1 ]
Sonmezisik, Muge [1 ]
Tarhan, Muhammet Salih [1 ]
Borcak, Deniz [1 ]
Ozdemir, Meryem Sahin [2 ]
Bayramlar, Osman Faruk [3 ]
Yesilbag, Zuhal [1 ]
Senoglu, Sevtap [1 ]
Gedik, Habip [1 ]
Karaosmanoglu, Hayat Kumbasar [1 ]
Yasar, Kadriye Kart [1 ]
机构
[1] Bakirkoy Dr Sadi Konuk Training Res Hosp, Dept Infect Dis & Clin Microbiol, TR-34140 Istanbul, Turkey
[2] Istanbul Univ, Cerrahpasa Fac Med, Dept Infect Dis & Clin Microbiol, TR-34098 Istanbul, Turkey
[3] Bakirkoy Dist Hlth Directorate, Dept Publ Hlth, TR-34140 Istanbul, Turkey
关键词
COVID-19; mortality; vaccination; CoronaVac; Pfizer-BioNTech; RISK-FACTORS; MORTALITY; PNEUMONIA;
D O I
10.1556/030.2022.01860
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We aimed to compare vaccinated and unvaccinated patients hospitalized with COVID-19 in terms of disease severity, need for intensive care unit (ICU) admission, and death. In addition, we determined the factors affecting the COVID-19 severity in vaccinated patients. Patients aged 18-65 years who were hospitalized for COVID-19 between September and December 2021 were retrospectively analyzed in three groups: unvaccinated, partially vaccinated, and fully vaccinated. A total of 854 patients were included. Mean age was 47.9 +/- 10.6 years, 474 patients (55.5%) were male. Of these, 230 patients (26.9%) were fully vaccinated, 97 (11.3%) were partially vaccinated, and 527 (61.7%) were unvaccinated. Of the fully vaccinated patients, 67% (n 5 153) were vaccinated with CoronaVac and 33% (n 5 77) were vaccinated with Pfizer-BioNTech. All patients (n 5 97) with a single dose were vaccinated with Pfizer-BioNTech. One hundred thirteen (13.2%) patients were transferred to ICU. A hundred (11.7%) patients were intubated and 77 (9.0%) patients died. Advanced age (P 5 0.028, 95% CI 5 1.00-1.07, OR 5 1.038) and higher Charlson Comorbidity Index (CCI) (P < 0.001, 95% CI 5 1.20-1.69, OR 5 1.425) were associated with increased mortality, while being fully vaccinated (P 5 0.008, 95% CI 5 0.23-0.80, OR 5 0.435) was associated with survival in multivariate analysis. Full dose vaccination reduced the need for ICU admission by 49.7% (95% CI 5 17-70) and mortality by 56.5% (95% CI 5 20-77). When the fully vaccinated group was evaluated, we found that death was observed more frequent in patients with CCI>3 (19.1 vs 5.8%, P < 0.01, OR 5 3.7). Therefore, the booster vaccine especially in individuals with comorbidities should not be delayed, since the survival expectation is low in patients with a high comorbidity index.
引用
收藏
页码:270 / 276
页数:7
相关论文
共 50 条
  • [31] Racial and Ethnic Disparities in Hospitalization and Clinical Outcomes Among Patients with COVID-19
    Serrano, Felipe
    Blutinger, Erik J.
    Vargas, Carmen
    Bilal, Saadiyah
    Counts, Christopher
    Straight, Matthew
    Lin, Michelle P.
    WESTERN JOURNAL OF EMERGENCY MEDICINE, 2022, 23 (05) : 601 - 612
  • [32] Clinical and immunological characteristics of vaccinated patients with COVID-19
    Ping Yu
    Huang Jianmin
    Fan Feifei
    Guo Yongjun
    Gou Jianjun
    Zhang Yi
    中华医学杂志英文版, 2022, 135 (14) : 1756 - 1758
  • [33] Clinical and immunological characteristics of vaccinated patients with COVID-19
    Ping, Yu
    Huang, Jianmin
    Fan, Feifei
    Guo, Yongjun
    Gou, Jianjun
    Zhang, Yi
    CHINESE MEDICAL JOURNAL, 2022, 135 (14) : 1756 - 1758
  • [34] Comparative Evaluation of the Clinical Severity of COVID-19 of Vaccinated and Unvaccinated Patients in Southeastern Romania in the First 6 Months of 2022, during the Omicron Wave
    Manole, Corina
    Baroiu, Liliana
    Nechita, Aurel
    Voinescu, Doina Carina
    Ciubara, Anamaria
    Debita, Mihaela
    Tatu, Alin Laurentiu
    Ciubara, Alexandru Bogdan
    Stefanopol, Ioana Anca
    Anghel, Lucretia
    Nechifor, Alexandru
    Firescu, Dorel
    HEALTHCARE, 2023, 11 (15)
  • [35] Liver dysfunction and clinical outcomes of unvaccinated COVID-19 patients with and without chronic hepatitis B
    Chang, Hao-Che
    Su, Tung -Hung
    Huang, Yu-Tsung
    Hong, Chun -Ming
    Sheng, Wang-Huei
    Hsueh, Po-Ren
    Kao, Jia-Horng
    JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2024, 57 (01) : 55 - 63
  • [36] Superspreading event of Covid-19 in adolescents: is there a difference between the vaccinated and the unvaccinated?
    Perelman, Carol
    Fastlicht, Andrea
    Sanchez-Flores, Alejandro
    Wegman-Ostrosky, Talia
    SALUD PUBLICA DE MEXICO, 2022, 64 (05): : 446 - 447
  • [37] COVID-19 in people with multiple sclerosis treated with ocrelizumab: Clinical outcomes in vaccinated patients
    Hauser, S. L.
    Gold, R.
    Cutter, G.
    Sauter, A.
    Fitovski, K.
    Schneble, H. M.
    Whitley, L.
    Jessop, N.
    Wang, Q.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 1002 - 1002
  • [38] Paxlovid Efficacy in Unvaccinated COVID-19 Patients: A Comprehensive Review of Outcomes
    Jehle, D.
    Paul, K.
    ANNALS OF EMERGENCY MEDICINE, 2024, 84 (04) : S29 - S29
  • [39] Comparison of Imaging Severity Between Vaccinated and Unvaccinated COVID-19 Patients: Perspective of an Indian District
    Singhal, Joy
    Goel, Chetan
    Gupta, Vinit
    Sachdeva, Mandeep
    Sanjappa, Shaurya
    Koushal, Vipin
    Singh, Inderpreet
    Tripathi, Akash
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (10)
  • [40] Receiving COVID-19 vaccine, hospitalization, and outcomes of patients with COVID-19: A prospective study
    Abdulah, Deldar Morad
    Mirza, Abbas Muhammed Sadiq
    MONALDI ARCHIVES FOR CHEST DISEASE, 2023, 93 (01)